Apollon Wealth Management LLC Makes New Investment in Agenus Inc. (NASDAQ:AGEN)

Apollon Wealth Management LLC acquired a new position in Agenus Inc. (NASDAQ:AGEN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 20,007 shares of the biotechnology company’s stock, valued at approximately $55,000. Apollon Wealth Management LLC owned about 0.09% of Agenus at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Walleye Capital LLC bought a new stake in shares of Agenus during the 3rd quarter worth approximately $1,003,000. BNP Paribas Financial Markets boosted its stake in shares of Agenus by 2,271.5% during the third quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 37,866 shares during the period. Geode Capital Management LLC grew its holdings in shares of Agenus by 7.1% in the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after purchasing an additional 32,016 shares during the last quarter. FMR LLC increased its stake in Agenus by 47.1% in the 3rd quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock worth $467,000 after buying an additional 27,309 shares during the period. Finally, Barclays PLC lifted its holdings in Agenus by 295.3% during the 3rd quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 20,777 shares in the last quarter. Institutional investors own 61.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a research note on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $10.00.

Agenus Trading Up 0.3 %

AGEN opened at $3.51 on Friday. Agenus Inc. has a 12 month low of $2.50 and a 12 month high of $19.69. The stock has a fifty day moving average price of $3.26 and a 200-day moving average price of $4.15. The firm has a market cap of $82.34 million, a price-to-earnings ratio of -0.31 and a beta of 1.31.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.